SINGAPORE – Whenever Professor Lee Tian Tee travelled, he needed to check with the airline or hotel whether he had access to a fridge because he needed one to store eye drops for his glaucoma, a condition where eye pressure increases due to a build-up of fluid inside the eye.
The eye condition can cause damage to the optic nerve and lead to blindness.
The Singaporean music professor, 61, was diagnosed with glaucoma in 2016 and had to live with the convenience of using medicated eye drops several times a day to reduce the pressure in his eyes.
In 2018, his eye doctor, Prof Paul Chew, a senior consultant at the National University Hospital’s (NUH) department of ophthalmology, invited him to be part of a clinical trial for a new implant being developed at the time.
The Paul Glaucoma Implant (PGI) was developed by Prof Chew, who is also from the Yong Loo Lin School of Medicine at the National University of Singapore (NUS), and a team of clinician-scientists from the National University Health System.
Clinical trials in Singapore were successfully carried out between December 2017 and December 2018 and the implants are now used by leading hospitals and established eye centres in 17 countries, including NUH here.
The implant comprises a tiny tube made of medical grade silicone that is implanted through the front of the eyeball, where it is secured with an endplate. The tube allows some fluid in the eye to flow out when pressure builds up, thus preventing optic nerve damage.
Prof Lee had the PGI inserted in his right eye in 2018 and then his left in 2019. The frequent traveller, who works at the Sichuan Conservatory of Music in Chengdu, China, now no longer needs eye drops to control his eye pressure.
Glaucoma implants have been around for 30 years, said Prof Chew, who has been researching the condition for 25 years.
PGI improves on existing implants by using a finer tube and an endplate with a larger surface area.
“We designed this implant to give higher successful eye pressure control and consistent safety and efficacy. It is a more reliable device than current standard devices in use today. The ability to predictably manage severe glaucoma is the result of this new implant,” Prof Chew said.
Depending on the type of glaucoma, treatment can take the form of medicated eye drops and laser treatment to reduce the eye pressure – but these may not be suitable for more severe forms of the disease.
Compared with eye drops and laser surgery, PGI reduces patients’ eye pressure for a longer period of time.
Associate Professor Victor Koh, head of the ophthalmology department at NUS Medicine and NUH, led the clinical trial of PGI.
Among the 82 patients in the trial, including Prof Lee, the implant successfully reduced the eye pressure in 93 per cent of them after one year.
Patients were also less dependent on eye drops after surgery as compared with other types of implants.
Prof Lee said that the implant has helped greatly in improving his quality of life.
“I have not used any eye drops since 2019. Every morning, I wake up without having to worry whether I will need to use eye drops or not. For a busy person like myself, it is really helpful.”